ClinicalTrials.gg
CompletedNCT04231968AIRFLOUpdated Feb 13, 2024

A Study of AK0529 in Chinese Infants Hospitalized With RSV

A Phase 3 interventional study of AK0529 and Matching placebo of AK0529 in Respiratory Syncytial Virus Infections, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 28 sites in China. Open to participants aged 1 Month to 24 Months. Per ClinicalTrials.gov, last updated 2024-02-13.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
1 Month to 24 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Enrollment
10th of 25
311 · median 132
Started
2020
the only one that year
Phase 3
6 of 30
2 open now
Registered
2nd of 30
by date
Lead sponsor
4 of 30
Shanghai Ark Biopharmaceutical Co., Ltd.

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 10th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2020, is one of 6 in phase 3, and was the 2nd registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 1 Month to 24 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, multicenter, phase III study to be conducted in infants hospitalized with RSV infection in China. The main objectives of this study are to investigate the efficacy and safety of AK0529 in Chinese infants.

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
1 Month to 24 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Male or female patients of any ethnicity with an age-adjusted for any prematurity of ≥1 month and ≤24 months.
  • Diagnosis of RSV infection by any virological means within 36 hours preceding the initial dose.
  • The time from the onset caused by RSV infection to the first dose should be ≤ 7 days. Time of onset is defined as the time the first respiratory or systemic signs or symptoms of RSV infection confirmed by the investigator.
  • Body weight ≥ 2.5 kg and ≤ 20 kg at screening.
  • For patients aged \<12 months, an occipitofrontal head circumference should be within the normal range for age and gender.
  • Bronchiolitis score ≥ 5.
  • The parent/legal guardian must have provided written for the patient to participate.

Main Exclusion Criteria:

  • Patients who have used any prohibited medications within 72 hours prior to expected administration and those who have used inhaled or systemic glucocorticosteroids within 24 hours prior to administration.
  • Patients (or mothers of patients younger than 6 months of age) with a known -positive history or patients highly suspected HIV-positive by the investigator.
  • Patients with known co-infection with influenza virus.
  • Patient known to have pneumonia caused by bacterial infection.
  • Patients requiring vasopressors or vasoactive drugs at the time of enrollment.
  • Concurrent gastrointestinal conditions that could seriously, in the opinion of the investigator, prejudice absorption of the Medicinal Product.
  • Bronchopulmonary dysplasia requiring assisted ventilation at the time of enrolment, except for the result of RSV infection.
  • Patients at risk for hypercapnia based on their medical history, except for the result of RSV infection.
  • Patient with airway malformations and congenital heart diseases, except for isolated patent ductus arteriosus and/or patent foramen ovale.
  • Renal failure including renal abnormalities likely to be associated with renal insufficiency.
  • Clinical evidence of hepatic decompensation.
  • Symptomatic because of congenital metabolic abnormality.
  • Chronic or persistent feeding difficulties.
  • Known or suspected to have primary immunodeficiency disease.
  • Any active or uncontrolled respiratory, cardiac, hepatic, central nervous system or renal disease unrelated to RSV infection at baseline, or any other medical condition that in the opinion of the investigator renders the patient unsuitable for enrolment; in case of any question, discuss such cases with the sponsor's medical monitor.
  • A history of epilepsy or seizures including febrile seizures.
  • History of family history of high allergies or allergies to multiple substances, or presence of severe rash that in the opinion or the investigator renders the patient unsuitable for enrollment.
  • The patient's parent or guardian is an employee of the investigator or the study site with direct involvement in the proposed study or other studies under the direction of that investigator of the study site, or any family members of the employees or the investigator.
  • Participation in an investigational drug or device study within 30 days prior to the date of screening.
  • Failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    AK0529

    Participants who are randomized to the experimental arm will receive AK0529 twice daily for five days .

    Drug: AK0529

  • Placebo comparator
    Placebo

    Participants in the control arm will be administered placebo at the matching dosage levels of active medications.

    Drug: Matching placebo of AK0529

Interventions

  • DrugAK0529

    AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.

    Also known as: ziresovir

  • DrugMatching placebo of AK0529

    The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.

06

What researchers measure

Primary outcomes

  1. Clinically significant change from baseline in bronchiolitis score on Day 3

    To demonstrate that AK0529 is superior to placebo in terms of changes from baseline in bronchiolitis signs and symptoms score. The differences of change in the bronchiolitis score are to be evaluated between the AK0529 and placebo arms after treatment. The total score is reported with a range from 0 to 12. Generally, each score component has a range of values from 0 to 3. A decreasing value of the total score represents a clinical improvement. Unless otherwise noted, the last non-missing measurement/assessment before the first dose of the investigational product is defined as the Baseline measurement. If a measurement/evaluation is performed on the same day of the first dose of the investigational product, these measurements will be considered as Baselines.

    Time frame: From Baseline (Pre-dose on Day 1) to Day 3 (48 hours)

Secondary outcomes

  1. Change from baseline in RSV (Respiratory syncytial virus) VL(viral load ) on Day 5

    To evaluate the antiviral effects of AK0529. The antiviral effects in infants hospitalized with RSV are to be determined by measuring the differences in viral load determined by RT-PCR between the AK0529 and placebo arms after treatment.

    Time frame: From Baseline (Pre-dose on Day 1) to Day 5 (96 hours)

  2. Proportions of subjects with a reduction from baseline in clinical bronchiolitis score ≥ 2 after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  3. Proportions of subjects with a reduction from baseline in clinical bronchiolitis score ≥ 3 after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  4. Proportions of subjects with a reduction from baseline in clinical bronchiolitis score ≥ 4 after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  5. Proportions of subjects with a reduction from baseline in clinical bronchiolitis score ≥ 5 after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  6. Proportions of subjects with symptom remission on Day 3 after treatment

    Symptom remission is defined as a reduction in clinical bronchiolitis score to 1 or 0 after treatment.

    Time frame: Day 3 (48 hours)

  7. Proportions of subjects with symptom remission at other visits after treatment

    Symptom remission is defined as a reduction in clinical bronchiolitis score to 1 or 0 after treatment.

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except for Day 3)

  8. Proportions of subjects with ≥ 75% reduction from baseline in bronchiolitis score on Day 3 after treatment

    Time frame: Day 3 (48 hours)

  9. Proportions of subjects with ≥ 75% reduction from baseline in bronchiolitis score at other visits after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except for Day 3)

  10. Proportions of subjects with disease remission on Day 3 after treatment

    Disease remission is defined as a reduction in bronchiolitis score to 1 or 0 after treatment, without non-invasive positive pressure ventilation or assisted mechanical ventilation or supplemental oxygen therapy.

    Time frame: From Baseline (Pre-dose on Day 1) to Day 3 (48 hours)

  11. Proportions of subjects with disease remission at other visits after treatment.

    Disease remission is defined as a reduction in bronchiolitis score to 1 or 0 after treatment, without non-invasive positive pressure ventilation or assisted mechanical ventilation or supplemental oxygen therapy.

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except for Day 3)

  12. Time from the first dose to symptom remission

    Symptom remission is defined as a reduction in clinical bronchiolitis score to 1 or 0 after treatment.

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  13. Time from the first dose to a zero general symptom score for subjects with general symptoms sub-scores equal to 3 at baseline

    The General Symptom score is part of the Bronchiolitis Score and has only two scores, 3 and 0. A normal patient is a 0, and the presence of irritable, lethargic, poor feeding is rated as 3.

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  14. Time from the first dose to a ≥ 75% reduction in bronchiolitis score

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  15. Time from the first dose to disease remission

    Disease remission is defined as a reduction in bronchiolitis score to 1 or 0 after treatment, without non-invasive positive pressure ventilation or assisted mechanical ventilation or supplemental oxygen therapy.

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  16. Change in bronchiolitis score and percentage change from baseline at each visit after treatment (except Day 3)

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except Day 3)

  17. Change from baseline in bronchiolitis sub-score at each visit after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  18. Proportions of subjects with the change in bronchiolitis sub-score values at each visit after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  19. Proportions of subjects achieving a ≥ 50% reduction from baseline in bronchiolitis score after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  20. Proportions of subjects achieving a ≥ 90% reduction from baseline in bronchiolitis score after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  21. Respiratory sequelae of subjects from the end of the safety observation period to Month 6

    The assessment of respiratory sequelae involves evaluating the frequency, duration, and treatment related to wheezing recurrences and the presence of confirmed asthma.

    Time frame: From Day 14 to Month 6

  22. Respiratory sequelae of subjects from the end of the safety observation period to the end of the second year

    The assessment of respiratory sequelae involves evaluating the frequency, duration, and treatment related to wheezing recurrences and the presence of confirmed asthma.

    Time frame: From Day 14 to end of Year 2

  23. Analysis of subjects admitted to intensive care unit (ICU) for diseases related to RSV infection

    Analyzed by the number of admissions, duration of admission, and the duration from the first dose to the end of ICU.

    Time frame: From Baseline to the end of ICU

  24. Analysis of subjects receiving non-invasive positive pressure ventilation or assisted mechanical ventilation

    Analyzed by the number of subjects receiving non-invasive positive pressure ventilation or assisted mechanical ventilation, duration of such ventilation, and the time from the first dose to the end of assisted ventilation.

    Time frame: From Baseline to Day 14

  25. Analysis of subjects receiving supplemental oxygen therapy

    Analyzed by the number of subjects receiving supplemental oxygen therapy, duration of such therapy, and the time from the first dose to supplemental oxygen therapy.

    Time frame: From first treatment to Day 14

  26. Proportions of subjects with RSV VL below the lower limit of quantification (LLOQ) on Day 5 after treatment

    Time frame: Day 5 (96hours)

  27. Proportions of subjects with RSV VL below the LLOQ at other visits

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except Day 5)

  28. Change from baseline in RSV VL at each visit except Day 5 after treatment

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14 (except Day 5)

  29. Area under the curve of RSV VL from baseline to the last measurement

    Time frame: From Baseline (Pre-dose on Day 1) to Day 14

  30. Analysis of clinical efficacy of AK0529 in different subgroups

    Analyzed in different subgroups categorized by, at a minimum, months of age, severity of baseline Bronchiolitis Score, time from onset of RSV infection to first dose, RSV viral subtypes, baseline RSV VL classifications, and doses.

    Time frame: From Baseline to Day 14

  31. Proportion of subjects with adverse events (AEs) occurring during the study

    To evaluate the safety and tolerability of AK0529.

    Time frame: From Baseline to Day 14

  32. Proportion of subjects with serious adverse events (SAEs) occurring during the study

    To evaluate the safety and tolerability of AK0529.

    Time frame: From Baseline to Day 14

  33. Proportion of subjects who withdraw from the study due to AEs during the study

    To evaluate the safety and tolerability of AK0529.

    Time frame: From Baseline to Day 14

  34. Maximum plasma concentration of AK0529 (Cmax)

    PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.

    Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)

  35. Plasma drug trough concentration of AK0529 (Ctrough)

    PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.

    Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)

  36. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)

    PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.

    Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)

  37. Apparent total body clearance (CL/F)

    PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.

    Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)

  38. Apparent volume of distribution (Vz/F)

    PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.

    Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)

  39. Elimination half-life (t½)

    PK parameters of AK0529 and its metabolites using population pharmacokinetic (POP-PK) and other appropriate methods.

    Time frame: At 3 and 24 hours after the first dose and on Day 6 (120 hours)

Other outcomes

  1. RSV VL and primary and selected secondary efficacy measurements

    To evaluate the relationship of antiviral effects of AK0529 to the primary and key secondary efficacy measurements.

    Time frame: From Baseline to Day 14

  2. Selective primary efficacy, secondary efficacy, and safety measures for the pharmacokinetic-pharmacodynamic (PK-PD) analysis

    To evaluate the PK-PD correlation between PK parameters and the values of bronchiolitis score and VL, including their respective changes.

    Time frame: From Baseline to Day 6

  3. Proportions of subjects with mutations at 20 reported sites associated with RSV fusion inhibitor-resistant mutations in RSV F genesequences after treatment compared to baseline

    To sequence the F gene of RSV in nasopharyngeal samples to the monitoring on the development of AK0529 resistance mutation. RSV F gene sequencing was performed with nasopharyngeal samples of subjects using Sanger sequencing.

    Time frame: From Baseline to Day 14

  4. Proportions of subjects detected with other respiratory disease-associated viruses at baseline

    To detect other common respiratory viruses in nasopharyngeal samples. Detection of respiratory disease-associated viruses includes coronaviruses, adenoviruses, metapneumoviruses, rhinoviruses, enteroviruses, influenza A viruses, influenza B viruses, parainfluenza viruses, and other viruses in baseline nasopharyngeal samples from subjects using microfluidic microarray methods.

    Time frame: Baseline (Pre-dose on Day 1)

  5. Changes in respiratory rate during the study

    To explore the difference in respiratory rate (bpm) with clinical significance between subjects on AK0529 and those on placebo.

    Time frame: From Baseline through Day 6

  6. Changes in heart rate during the study

    To explore the difference in heart rate/pulse (bpm) with clinical significance between subjects on AK0529 and those on placebo.

    Time frame: From Baseline through Day 6

  7. Changes in body temperature during the study

    To explore the difference in body temperature (Celsius) with clinical significance between subjects on AK0529 and those on placebo.

    Time frame: From Baseline through Day 6

  8. Changes in systolic blood pressure during the study

    To explore the difference in systolic blood pressure (mmHg) with clinical significance between subjects on AK0529 and those on placebo.

    Time frame: From Baseline through Day 6

  9. Changes in diastolic blood pressure during the study

    To explore the difference in diastolic blood pressure (mmHg) with clinical significance between subjects on AK0529 and those on placebo.

    Time frame: From Baseline through Day 6

  10. Changes in SpO2 during the study

    To explore the difference in SpO2 (%) with clinical significance between subjects on AK0529 and those on placebo.

    Time frame: From Baseline through Day 6

  11. Duration of hospitalization of subjects with RSV infection

    To explore the differences in other clinical measurements between subjects on AK0529 and those on placebo.

    Time frame: From the day of patient admission to the day of patient discharge

  12. Time from first dose to discharge of subjects with RSV infection

    To explore the differences in other clinical measurements between subjects on AK0529 and those on placebo.

    Time frame: From Baseline (Day 1) to the day of patient discharge

07

Study locations

28 sites
  • Beijing Children's Hospital
    Beijing, 100045, China
  • Peking University Third Hospital
    Beijing, 100191, China
  • The First Bethune Hospital of Jilin University
    Changchun, 130021, China
  • Hunan Provincial People's Hospital
    Changsha, 410005, China
  • West China Women's and Children's Hospital
    Chengdu, 610041, China
  • Children's Hospital of Chongqing Medical University
    Chongqing, 401122, China
  • Guangzhou Women and Children's Medical Center
    Guangzhou, 510623, China
  • The Children's Hospital of Zhejiang University School of Medicine
    Hangzhou, 310030, China
  • Liaocheng People's Hospital
    Liaocheng, 252000, China
  • Jiangxi Provincial Children's Hospital
    Nanchang, 330006, China
  • Children's Hospital of Nanjing Medical University
    Nanjing, 210008, China
  • Jiangsu Province Hospital
    Nanjing, 210029, China
  • The First Affiliated Hospital of Guangxi Medical University
    Nanjing, 530021, China
  • Hainan Third People's Hospital
    Sanya, 572000, China
  • Children's Hospital of Shanghai
    Shanghai, 200062, China
  • Shanghai Children's Medical Center
    Shanghai, 200127, China
  • Shengjing Hospital of China Medical University
    Shengyang, 110004, China
  • Shenzhen Children's Hospital
    Shenzhen, 518026, China
  • Children's Hospital of Soochow University
    Suzhou, 215002, China
  • Tianjin Children's Hospital
    Tianjin, 300074, China
  • The Second Affiliated Hospital and Yuying Children's Hospital of WMU
    Wenzhou, 325027, China
  • Wuhan Children's Hospital
    Wuhan, 430016, China
  • Wuxi Children's Hospital
    Wuxi, 214023, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, 361003, China
  • Xiamen Maternity and Child Healthcare Hospital
    Xiamen, 361100, China
  • Henan Children's Hospital
    Zhengzhou, 450018, China
  • The Third Affiliated Hospital of Zhengzhou University
    Zhengzhou, 450052, China
  • Boai Hospital of Zhongshan
    Zhongshan, 528402, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jan 2022, 15 months.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 15 months is above that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2020
First posted
Jan 18, 2020
StartActual
Sep 22, 2020
Primary completionActual
Jan 21, 2022
CompletionActual
Feb 2, 2022
Last update
Feb 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04231968
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Sep 22, 2020
Primary completion
Jan 21, 2022
Completion
Feb 2, 2022
Last update
Feb 13, 2024

Study contacts

Yu Chen, MD
study director · yu.chen@arkbiosciences.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion